在慢性髓性白血病中出现不同类型的BCR-ABL抑制剂的皮疹:系统性审查和元分析
Su Li1, Tingwen Wang2, Yu Zhong1
1Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, Liaoning Province, PR China.
Future oncology (London, England)
|June 27, 2023
概括
新的BCR-ABL抑制剂在慢性髓性白血病 (CML) 患者中显示出与伊马替尼布类似的皮疹风险. 然而,尼洛替尼,博苏替尼和波纳替尼可能会增加皮疹发生率,需要注意皮肤毒性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性骨髓性白血病 (CML) 是一种骨髓增殖性瘤.
- BCR-ABL氨酸激酶抑制剂 (TKI) 是对CML的标准治疗方法.
- 皮肤毒性是TKI的常见副作用.
研究的目的:
- 在接受不同BCR-ABL抑制剂治疗的CML患者中,系统地审查和元分析所有级和高级皮疹的风险.
- 为了比较与新一代BCR-ABL抑制剂相关的皮疹发生率与意马替尼.
主要方法:
- 一项对2000年至2022年4月期间发表的12项研究的元分析.
- 在PubMed,Cochrane图书馆,Embase和ClinicalTrials.gov.gov进行的文献搜索.
主要成果:
- 使用新一代BCR-ABL抑制剂的所有等级或高等级皮疹的发生率与标准剂量伊马替尼的发生率没有显著差异.
- 亚组分析显示,与意马替尼相比,尼洛替尼,博苏替尼和波纳替尼对所有级别皮疹的发病率更高.
结论:
- 在接受尼洛替尼,博苏替尼和波纳替尼治疗的CML患者中,应密切监测皮肤毒性,特别是皮疹.
- 虽然整体皮疹风险可能相似,但特定的新型TKI与皮疹发病率的增加有关.
相关概念视频
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K


